 In the England, medicines for rare diseases may not be selected for appraisal, while The Netherlands applies a budgetary cut-off of €2.5 M for inpatient drugs. Canada and New Zealand are in the process of review and implementation of different processes for rare drugs.
A Comparison of International Health Technology Assessment SystemsDoes the Perfect System Exist?
Annette  Common themes that emerge in the recommendations of these organizations are:
1. The HTA system should be 'procedurally fair' with clear processes for assessment and decision-making, scope for pragmatic approaches and an appeal mechanism.
Introduction
 A survey was designed to collect information on the processes employed in countries with well-established HTA systems to determine how each country is performing relative to the recommendations for good practice in HTA and to allow comparison between countries. The countries surveyed were England, Scotland, Ireland, France, Germany, Italy, The Netherlands, Portugal, Sweden, Canada, Australia, New Zealand, South Korea and Taiwan.
 A total of sixty questions were developed, collecting information on process, methodology, data requirements, societal input and transparency and the responses grouped to address the concepts outlined above.
 The survey was completed by staff working in Roche affiliates with first-hand experience developing submissions and working with the HTA bodies in their country. The survey was completed between December 2013 and January 2014, with additional checks of data accuracy conducted through July to September 2014.
Methods

Stakeholder involvement
 All countries consult clinicians as needed for input into decision making. Most countries also consult academia for input into the development of HTA methodology and guidelines. In terms of setting the criteria used to guide decision-making (eg. ICER thresholds), few countries involve academics or ethicists and only the UK and Taiwan involve citizens. (Figure  3 ). This appears to be at odds with the goal of HTA which is to represent societal values in relation to allocation of scarce resources.
 Patient and/or citizen involvement in individual funding decisions ranges from none, to input via a public submission process, inclusion on the independent HTA committee and meetings being held in public (Figure 4 ).
Procedural fairness
 In all HTA systems, an independent committee conducts or reviews assessments. However, in most countries, the government (Health Minister or a government appointed body) makes the final funding decision or has the ability to overrule the Committee.
 Even in countries where the independent committee makes the final decision, government influence may be exerted via membership of the committee (Italy and Sweden). Some form of appeal is possible in most countries, but this ranges in the extent of independence. In general, countries without a formal appeal mechanism allow resubmissions with new information to be made by the drug sponsor ( Figure 1 ). 
Results
* Quebec province only. # Consider indirect costs, although little weight is attributed  While most HTA systems employ independent committees, government/payer involvement in decision making is common.
 The Netherlands, Sweden and Quebec province (Canada) routinely consider indirect costs in the assessment process. Formal criteria for wider societal factors considered in decisionmaking are lacking, leading to reduced transparency, a common concern in all systems. Several countries are now investigating multi-criteria decision making.
 The UK has invested heavily in processes to ensure stakeholder involvement but a focus on a fixed ICER threshold remains in decision making.
 There is a growing trend towards adoption of a different or more fit-for-purpose process for drugs for the treatment of rare diseases or with low budget impact. 
Conclusion
